Drug intelligence / Profile preview

GB-AOS7

Development stage: Preclinical
Lead developer: GlycosBio
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Topical

Overview

GB-AOS7 is a preclinical-stage therapeutic candidate being developed by GlycosBio for the treatment of cold sores (herpes labialis). The drug utilizes GlycosBio's proprietary Activated Oil System (AOS), a lipid-based delivery technology designed to optimize the topical administration and penetration of active ingredients into the skin. By leveraging this platform, GB-AOS7 aims to provide improved clinical outcomes for viral skin lesions compared to conventional topical treatments. As of 2024, the program remains in preclinical development, approaching clinical-stage evaluation.

Beyond the preview

Go deeper on GB-AOS7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-AOS7.

Explore the full profile